GRI Bio, Inc. (GRI), a biotechnology company, Wednesday announced preclinical data showing that its lead drug candidate GRI-0621 has both anti-inflammatory and anti-fibrotic effects in pulmonary fibrosis.
The data were presented at the 2025 ATS International Conference.
GRI-0621 is currently being evaluated in a Phase 2a study in patients with Idiopathic Pulmonary Fibrosis (IPF). Topline results from the study are expected in the third quarter of 2025.
Results from 6-week interim analysis in ongoing Phase 2a study of GRI-0621 are anticipated in the second quarter of 2025.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.